Disease · EFO_0008526

status epilepticus

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. status epilepticus. Diseases, record EFO_0008526. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0008526

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: status epilepticus; Open Targets
Open Targets ID: EFO_0008526; Open Targets
Disease Ontology: DOID:1824; Disease Ontology
MeSH: D013226; MeSH
NCI Thesaurus: C85079; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 28 drugs, from DailyMed and PMDA; Open Targets

Drugs28

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LORAZEPAM	CHEMBL580	Small molecule	Approval	DailyMed and PMDA	11	9	9	Drugs and targets
MIDAZOLAM	CHEMBL655	Small molecule	Approval	DailyMed and PMDA	8	6	6	Drugs and targets
PHENOBARBITAL SODIUM	CHEMBL149972	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
LEVETIRACETAM	CHEMBL1286	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
VALPROIC ACID	CHEMBL109	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
KETAMINE	CHEMBL742	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
GANAXOLONE	CHEMBL1568698	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
BREXANOLONE	CHEMBL207538	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DIAZEPAM	CHEMBL12	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
FOSPHENYTOIN	CHEMBL1201336	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 28

See all 28 drugs

Targets51

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	12	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	12	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	12	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	12	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	12	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	12	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	12	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	12	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	12	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	12	GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 51

See all 51 targets

Trials47

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00809146	Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications	Phase 3	1,023	2012-04-13	Status Epilepticus	LORAZEPAM, MIDAZOLAM	Its record names the disease	ClinicalTrials.gov
NCT01960075	Established Status Epilepticus Treatment Trial	Phase 3	478	2020-02-28	Benzodiazepine Refractory Status Epilepticus	FOSPHENYTOIN, LEVETIRACETAM, VALPROIC ACID	Its record names the disease	ClinicalTrials.gov
NCT03905798	LORA-PITA IV General Investigation		206	2025-03-10	Status Epilepticus	LORAZEPAM	Its record names the disease	ClinicalTrials.gov
NCT02477618	A Study With SAGE-547 for Super-Refractory Status Epilepticus	Phase 3	132	2019-05-02	Super-Refractory Status Epilepticus	BREXANOLONE	Its record names the disease	ClinicalTrials.gov
NCT04391569	Randomized Therapy In Status Epilepticus	Phase 3	100	2025-05-29	Status Epilepticus	GANAXOLONE	Its record names the disease	ClinicalTrials.gov
NCT02239380	Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan	Phase 3	26	2019-02-18	Status Epilepticus	LORAZEPAM	Its record names the disease	ClinicalTrials.gov
NCT02052739	Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus	Phase 1/2	25	2022-05-03	Super-refractory Status Epilepticus	BREXANOLONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03336645	Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan	Phase 3	25	2020-07-31	Nervous System Diseases	MIDAZOLAM HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00265616	Treatment of Refractory Status Epilepticus	Phase 3	23	2013-04-04	Status Epilepticus	PENTOBARBITAL, PROPOFOL, THIOPENTAL	Its record names the disease	ClinicalTrials.gov
NCT03350035	Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus	Phase 2	17	2022-12-15	Status Epilepticus, Convulsive Status EPILEPTICUS, Non Convulsive Status Epilepticus, Epilepsy	GANAXOLONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 47

See all 47 trials

Comparisons in its trials28

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
IM Midazolam vs IV Lorazepam: serious adverse events	137 of 514	156 of 509	1,023	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects Admitted to an Intensive Care Unit (ICU)	128 of 448	161 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With Recurrent Seizure Within 12 Hours After ED Arrival	51 of 448	47 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With Endotracheal Intubation Within 30 Min After ED Arrival	63 of 448	64 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With Termination of Seizures at ED Arrival With no Rescue Therapy Given	329 of 448	282 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With Hypotension	12 of 448	13 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects Hospitalized	258 of 448	292 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With IM Injection-site Complications	4 of 448	2 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With IV Injection-site Complications	0 of 448	3 of 445	893	NCT00809146	Trial comparisons
SAGE-547 vs Placebo: Number of Participants Able to be Weaned Off All Third-line Agents Before the End of the First SAGE-547 or Placebo Infusion	38 of 66	45 of 66	132	NCT02477618	Trial comparisons

1 to 10 of 28

See all 28 comparisons in its trials

Papers from its trials34

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39254674	RESULT	1	PubMed
36333039	RESULT	1	PubMed
34454654	RESULT	1	PubMed
34286464	RESULT	1	PubMed
33664203	RESULT	1	PubMed
29356811	RESULT	1	PubMed
28295226	RESULT	1	PubMed
25616473	RESULT	1	PubMed
20878265	RESULT	1	PubMed
17199030	RESULT	1	PubMed

1 to 10 of 34

See all 34 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0008526

GET https://conductscience.org/api/diseases/v1/EFO_0008526/drugs?page=2

API reference For AI assistants